Legislation
Letter to Dr. Margaret Hamburg, FDA Commissioner, about maintaining and strengthening conflict of interest policies for advisory committees
In this letter to FDA Commissioner, Dr. Margaret Hamburg, NRC and other coalition members advocate for stronger conflict of interest requirements for members of FDA advisory committees to protect patients and consumers against industry biases. | more
Report: Medical Devices Lack Evidence of Safety and Effectiveness
July 29, 2011. The prestigious Institute of Medicine (IOM) released a report on the Food and Drug Administration's 510(k) medical device clearance process stating the system is "flawed" and should be revised. The report echoes the National Research Center for Women & Families' concerns about the lack of evidence that these devises actually work and are safe. | more
Letter to Maine House of Representatives on the Children’s Wireless Protection Act
The Children's Wireless Protection Act, 02/26/2010. | more
Statement by Diana Zuckerman on Maryland’s Senate Bill 213 “Child Care Articles and Toys Containing Bisphenol-A Prohibition,” February 17, 2010
The Cancer Prevention and Treatment Fund strongly supports Senate Bill 213, which will help to ensure that Maryland's children are better protected from the adverse health effects of BPA. | more
Letter to Hon. Andrea M. Boland, Maine House of Representatives, in support of “Children’s Wireless Protection Act,” February 1, 2010
The Cancer Prevention and Treatment Fund of the National Research Center for Women & Families strongly supports your pioneering, proactive legislation. The "Children's Wireless Protection Act" would help protect the health of Maine residents by making the state the first to require warning labels that radiation from cell phones may cause brain cancer. | more
Statement of Dr. Diana Zuckerman before the DC Committee on Government Operations and the Environment regarding Bisphenol A and Phthalates, January 20, 2010
The Cancer Prevention and Treatment Fund of the National Research Center for Women & Families strongly supports Bill 18-521, the "Human and Environmental Health Protection Amendment Act of 2009," which will help to ensure that children and residents of the District of Columbia are better protected from the adverse health affects of a variety of chemicals. | more
Patient and Consumer Coalition Letter to Congressional Leaders, January 8, 2010
The Cancer Prevention and Treatment Fund/National Research Center for Women & Families, as part of the Patient and Consumer Coalition, urges that the House language on comparative effectiveness research be included when the House and Senate health care bills are reconciled. The House language places the center for comparative effectiveness research in the Agency for Healthcare Research and Quality (AHRQ) to minimize industry conflicts-of-interests and ensure scientific objectivity. This will benefit patients by reducing the use of ineffective and potentially dangerous treatments and medical tests. | more
Patient and Consumer Coalition Letter to Congressional Leaders, March 18, 2009
The Cancer Prevention and Treatment Fund/National Research Center for Women & Families, as part of the Patient and Consumer Coalition, strongly supports H.R. 1523, the "Ban Poisonous Additives Act of 2009," which will remove Bisphenol A (BPA) from food and beverage containers. The Centers for Disease Control and Prevention (CDC) found BPA in more than 90 percent of Americans tested for the chemical, and BPA is linked to numerous adverse health effects. We are particularly concerned about BPA's effects on pregnant women. Scientists have reported that BPA adversely affects the health of fetuses (along with infants and children) at currently exposed levels. We are also gravely concerned about BPA's effect on chemotherapy patients, especially those with breast cancer. | more
